Advances in basic and clinical immunology in 2016 - 05/10/17
, Yousef R. Badran, MD b, ∗, Raif S. Geha, MD b, Janet S. Chou, MD b, Ari J. Fried, MD bAbstract |
Advances in basic immunology in 2016 included studies that further characterized the role of different proteins in the differentiation of effector T and B cells, including cytokines and proteins involved in the actin cytoskeleton. Regulation of granule formation and secretion in cytotoxic cells was also further described by examining patients with familial hemophagocytic lymphohistiocytosis. The role of prenylation in patients with mevalonate kinase deficiency leading to inflammation has been established. We reviewed advances in clinical immunology, as well as new approaches of whole-genome sequencing and genes newly reported to be associated with immunodeficiency, such as linker of activation of T cells (LAT); B-cell CLL/lymphoma 11B (BCL11B); RGD, leucine-rich repeat, tropomodulin domain, and proline-rich domain–containing protein (RLTPR); moesin; and Janus kinase 1 (JAK1). Trials of hematopoietic stem cell transplantation and gene therapy for primary immunodeficiency have had relative success; the use of autologous virus-specific cytotoxic T cells has proved effective as well. New medications are being explored, such as pioglitazone, which is under study for its role in enhancing the oxidative burst in patients with chronic granulomatous disease. Development of vaccines for HIV infection continues to provide insight into the immune response against a virus with an extraordinary mutation rate.
Le texte complet de cet article est disponible en PDF.Key words : Immunology, primary immunodeficiency, whole-exome sequencing, hematopoietic stem cell transplantation, common variable immunodeficiency, severe combined immunodeficiency, hyper-IgE syndrome
Abbreviations used : AIP1, APDS, BCL11B, BCR, CARD9, CC, CD40L, CE, CGD, CNV, COPA, CTLA-4, CVID, DN, DOCK8, FHL, GEF, HIES, HLH, HPS2, HSCT, ILC, iPSC, JAK1, KIR, LAT, LFA-1, LRBA, LYST, mTOR, MVK, nAIGA, NF-κB, NGS, NK, OS, OTULIN, PID, PI3K, POLE2, PRF1, PTEN, RAG1, RLPR, ROS, RV, SCID, S1P, STAT, STING, TAP1, TCR, TFH, TFRC, THI, TLR, TMEM, UNG, VST, WAS, X-HIGM
Plan
| Disclosure of potential conflict of interest: J. S. Chou is employed by Boston Children's Hospital and has received a grant from the National Institute of Allergy and Infectious Disease. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 140 - N° 4
P. 959-973 - octobre 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
